Dr. Arkenau on Advancements on Horizon in Gastric Cancer

Hendrik-Tobias Arkenau, MD, PhD
Published: Wednesday, Jul 27, 2016


Hendrik-Tobias Arkenau, MD, PhD, founding medical director, executive medical director, Sarah Cannon Research Institute UK, discusses immunotherapy advancements on the horizon in the field of gastric cancer.
 
Combination regimens, such as PD-1 plus CTLA-4 agents, are currently being explored, Arkenau explains. Recent data that were presented at the 2016 ASCO Annual Meeting demonstrate promise with the management of checkpoint blockade as well as OX40 agonists, which are designed to create co-stimulatory effects on T cells.

Additional data that were presented show intriguing results of a PD-1 and OX40 combination regimen, in that it did not show any additional toxicities nor any drug-to-drug interaction, he adds.
SELECTED
LANGUAGE

Hendrik-Tobias Arkenau, MD, PhD, founding medical director, executive medical director, Sarah Cannon Research Institute UK, discusses immunotherapy advancements on the horizon in the field of gastric cancer.
 
Combination regimens, such as PD-1 plus CTLA-4 agents, are currently being explored, Arkenau explains. Recent data that were presented at the 2016 ASCO Annual Meeting demonstrate promise with the management of checkpoint blockade as well as OX40 agonists, which are designed to create co-stimulatory effects on T cells.

Additional data that were presented show intriguing results of a PD-1 and OX40 combination regimen, in that it did not show any additional toxicities nor any drug-to-drug interaction, he adds.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x